Breaking News

Tweet TWEET

Update: Alexza to Report 2013 First Quarter Financial Results on Tuesday, May 14, 2013

Update: Alexza to Report 2013 First Quarter Financial Results on Tuesday, May
                                   14, 2013

PR Newswire

MOUNTAIN VIEW, Calif., May 1, 2013

MOUNTAIN VIEW, Calif., May 1, 2013 /PRNewswire/ --Alexza Pharmaceuticals,
Inc. (Nasdaq: ALXA) will report results for its fiscal quarter ended March 31,
2013 on Tuesday, May 14, 2013, following the close of the U.S. financial
markets. The Company will also host an investor conference call and live
webcast on the same day at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to
provide a company update and discuss the financial results.

To access the conference call and webcast via the Internet, go to
www.alexza.com, under the "Investor Relations" link. Please join the call at
least 15 minutes prior to the start of the call to ensure time for any
software downloads that may be required. Interested parties may also
pre-register at
https://www.theconferencingservice.com/prereg/key.process?key=PGMFTRGGW.

To access the live conference call, dial 888-680-0865 (domestic) or
+1-617-213-4853 (international). The reference number to enter the call is
11579408.

The replay of the conference call may be accessed at www.alexza.com under the
"Investor Relations" link, or by dialing 888-286-8010 (domestic) or
+1-617-801-6888 (international). The reference number for the replay of the
call is 72153700. A replay of the call will be available for two months
following the event.

About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development and
commercialization of novel, proprietary products for the acute treatment of
central nervous system conditions, including agitation, acute repetitive
seizures and insomnia. Alexza's products are based on the Staccato^® system,
a hand-held inhaler that is designed to deliver a drug aerosol to the deep
lung, providing rapid systemic delivery and therapeutic onset with ease and
convenience for patients.

ADASUVE^® (Staccato loxapine) is Alexza's first product, which was approved by
the U.S. Food and Drug Administration in December 2012 and by the European
Medicines Agency in February 2013. Grupo Ferrer Internacional, S.A. is
Alexza's commercial partner for ADASUVE in Europe, Latin America, Russia and
the Commonwealth of Independent States countries. The commercial launch of
ADASUVE is projected for the third quarter 2013 in the U.S. and Europe.

For more information about Alexza, the Staccato system technology or the
Company's development programs, please visit www.alexza.com. For more
information about ADASUVE, please visit www.adasuve.com.

ADASUVE^® and Staccato^® are registered trademarks of Alexza Pharmaceuticals,
Inc.

Safe Harbor Statement
The anticipated news release and conference call will contain forward-looking
statements that involve significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a forward-looking
statement, as defined in the Private Securities Litigation Reform Act of 1995,
and should be considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the ability for Alexza and
Ferrer to effectively and profitably commercialize ADASUVE, the timing of the
projected commercialization of ADASUVE, the adequacy of the Company's capital
to support the Company's operations, and the Company's ability to raise
additional funds and the potential terms of such potential financings. The
Company's forward-looking statements also involve assumptions that, if they
prove incorrect, would cause its results to differ materially from those
expressed or implied by such forward-looking statements. These and other risks
concerning Alexza's business are described in additional detail in the
Company's Annual Report on Form 10-K for the year ended December 31, 2012 and
the Company's other Periodic and Current Reports filed with the Securities and
Exchange Commission. Forward-looking statements contained in this announcement
are made as of this date, and the Company undertakes no obligation to publicly
update any forward-looking statement, whether as a result of new information,
future events or otherwise.

SOURCE Alexza Pharmaceuticals, Inc.

Website: http://www.alexza.com
Contact: BCC Partners, Karen L. Bergman, 650.575.1509,
kbergman@bccpartners.com or Michelle Corral,415.794.8662,
mcorral@bccpartners.com
 
Press spacebar to pause and continue. Press esc to stop.